Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) rose 0.15% to $48 in after-hours trading on Tuesday on news the European Commission approved its Empliciti (elotuzumab) drug for the treatment of adult patients with multiple myeloma.

Bristol-Myers Squibb Gains Europe's Approval for Empliciti

Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.

Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion

Avista

Broadcom

CVS Health

Gap Inc

International Game Technology

Kellogg

SL Green Realty

State Street

These 10 stocks don't quite qualify as "set it and forget it" plays. All have some degree of risk.

10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond

In January 2019, Bristol-Myers Squibb announced it will acquire Celgene and the acquisition will be closed at the end of 2019 or beginning of 2020.

Bristol-Myers Squibb: Great Deal On Celgene And Undervalued

Amgen

Celgene

Mylan

Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.

4 Biotech Stocks to Buy That Are on the Move

Exact Sciences

Guardant Health Inc

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

3 Cancer Treatment Stocks to Enrich Your Portfolio

Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.

Bristol-Myers Announces Sale of Celgene's Otezla to Amgen

Aurora Cannabis

Foot Locker

Netflix

Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.

5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY & FL

Intuitive Surgical

Myriad Genetics

Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.

Three Cancer Treatment Stocks - to Buy Right Now

Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Why Is Bristol-Myers (BMY) Up 2.6% Since Last Earnings Report?

Bristol-Myers Squibb’s (NYSE:BMY) Eliquis is a leading novel oral anticoagulant, which refers to blood thinners that treats, prevents, and reduces the risk of blood clotting. Other NOACs include Johnson & Johnson’s Xarelto, Boehringer Ingelheim’s Pradaxa, Daiichi Sankyo’s Lixiana and Savaysa, and.

Can Eliquis Continue To Add $1 Billion In Annual Sales For Bristol-Myers Squibb?

Baxter

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Cardinal Health

Healthpeak Properties Inc

Healthcare stocks are among the best growth and income plays. Here are five firms in the sector that have the goods to keep growing and paying strong dividends.

5 Healthcare Stocks to Buy for Healthy Dividends

Commercial Metals

Delta Air Lines

United Continental Hlds

Earnings yield is quite effective for determining undervalued stocks.

4 High Earnings Yield Stocks to Bolster Your Portfolio

Anglogold Ashanti Plc

JD.com

M/I Homes

Fears of recession ebb after White House considers tax cuts for millions of workers, China unveils new interest rate reforms and Germany hints at stimulus measures.

Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers

Drug manufacturers are under pressure due to patent expirations and political pressure to reduce healthcare costs. In the case of Bristol-Myers Squibb, the Celgene acquisition is an additional risk factor.

Bristol-Myers Squibb Is Undervalued

Bristol-Myers Squibb’s (NYSE:BMY) stock price has fallen by over 35% over the last three years, despite a growth in revenues, margins, and earnings. The decline can be attributed only to contraction in the price to earnings multiple.

What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years?

AbbVie

Illumina

Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

5 Top Cancer-Fighting Stocks to Buy Now

Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick Bristol-Myers Squibb (BMY) Stock?

Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.

Bristol-Myers Squibb Stock Has Upside — But Mind the Risks

Bristol-Myers is expected to close on the Celgene merger around year-end.

Celgene: Timing The Switch To Bristol-Myers

Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its merger with Celgene. Is now the right time to buy BMY stock?

BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?

BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
The post Fear Around Bristol-Myers Squibb Stock is Starting to Fade appeared first on InvestorPlace.

Fear Around Bristol-Myers Squibb Stock is Starting to Fade

Johnson & Johnson

Merck

Pfizer

These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Alaska Air Group

Earnings yield is very useful for determining undervalued stocks.

4 High Earnings Yield Stocks to Strengthen Your Portfolio

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

News for Bristol-Myers Stock (BMY)